Watchman FLX Pro CT Pilot Study

About the study

The primary objective of this study is to measure device tissue coverage post-implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device (WATCHMAN FLX Pro) using the serial advanced imaging modalities of cardiac computed tomography (CT) and transesophageal echocardiography (TEE) and assess its relationship, if any, to clinical events.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Subject is of legal age to participate in the study per the laws of their respective geography.
Subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve).
Subject is clinically indicated for a WATCHMAN FLX Pro device.
Subject is deemed suitable for the protocol-defined pharmacologic regimen.
Subject or legal representative is able to understand and willing to provide written informed consent to participate in the study.
Subject is able and willing to return for required follow-up visits and examinations.

EXCLUSION CRITERIA

Exclusion Criteria:

Exclusion criteria are listed below.

Subject is currently enrolled in another investigational study, except if the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatment.

Subject has eGFR <30 mL/min (chronic kidney disease stage IV or stage V).

Subject is contraindicated for TEE.

Subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction (e.g., due to an underlying hypercoagulable state).

Subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to, cardioversion, percutaneous coronary intervention, cardiac ablation, cataract surgery, etc.).

Subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or TIA within the 30 days prior to enrollment.

Subject had a prior major bleeding event per ISTH definitions within the 30 days prior to enrollment. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source are a further exclusion regardless of timing of the bleeding event.

Subject has an active bleed.

Subject has a reversible cause for AF or has transient AF.

Subject has no LAA or the LAA is surgically ligated.

Subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment.

Subject has a history of atrial septal repair or has an atrial septal defect/patent foramen ovale (ASD/PFO) device.

Subject has a known contraindication to percutaneous catheterization procedure.

Subject has a cardiac tumor.

Subject has signs/symptoms of acute or chronic pericarditis.

Subject has an active infection.

There is evidence of tamponade physiology.

Subject has New York Heart Association Class IV congestive heart failure at the time of enrollment.

Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment per study physician's discretion).

Subject has a documented life expectancy of less than 6 months.

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details

Contition

Non-valvular Atrial Fibrillation (AF)

Age (in years)

18 - 90

Phase

Not Applicable

Participants needed

Est. Completion Date

Jul 31, 2024

Treatment type

Interventional

Sponsor

Boston Scientific Corporation

ClinicalTrials.gov identifier

NCT05567172

Study number

S2517

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?